ROR1 and sarcoma: EGFR, GD2, insulin-like growth factor 1 receptor (IGF-1R), tyrosine kinase orphan-like receptor 1 (ROR1), CD44v6, and NK cell activating receptor group 2-member D (NKG2D) are potential targets in sarcoma, and early phase trials are underway to investigate the efficacy of CAR therapies for these targets.